you are here: Home News Dr Reddys

Dr Reddys

Dr Reddy’s warns of 'huge monetary loss' in plea against FSSAI order on ORS
Reduce Dr Reddys; target of Rs 1200: Emkay Global Financial
USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?
Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports
Gainers & Losers: Top 10 stocks that moved the most on July 24
Dr Reddy's Laboratories shares rise 3% after Q1; should you buy, sell or hold?
Dr Reddy’s Q1 earnings quite in line; focus now shifts to key launches ahead
Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth
Morgan Stanley initiates coverage on pharma players, bullish only on Sun Pharma
Gainers & Losers: Top 10 stocks that moved the most on June 26
Dr Reddy's shares drop 2% as Citi trims target price; sees 26% downside
Delhi High Court restrains Dr.Reddy’s, OneSource from domestic sale of weight loss drug amid patent dispute
Pharma shares sulk on Trump's plan to reduce reliance on foreign-made medicines
Dr Reddy's to introduce Sanofi's novel drug in India
Nifty Pharma settles 2% higher on exclusion from Trump's reciprocal tariffs; Lupin, IPCA Labs up 5%
GV Prasad of Dr Reddy's says 25% tariff on pharma exports could make medicines costlier for US consumers
Will Trump’s tariffs assail Indian pharma, or can it sail through?
Sell Dr Reddys; target of Rs 1150: Emkay Global Financial
Q3 Results 2025 Highlights: Adani Green Energy sees profit surge while Mankind Pharma posts revenue growth amid profit decline
Gainers & Losers: 10 stocks that moved the most on December 20
Senores IPO: A B2B play in pharma generics
Dr Reddy's unit gets penalty of Rs 28.7 lakh from Kazakhstan authority
Sell Dr Reddy's; target of Rs 1070: Emkay Global Financial
Dr Reddy's R&D expenses to stay around 8.5% in FY25, to launch key biosimilar in 2027
Dr Reddy’s enters pact with Gilead Sciences to manufacture, sell HIV drug Lenacapavir in India and 120 countries

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Dr Reddys

Dr Reddy’s warns of 'huge monetary loss' in plea against FSSAI order on ORS

Reduce Dr Reddys; target of Rs 1200: Emkay Global Financial

USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?

Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports

Gainers & Losers: Top 10 stocks that moved the most on July 24

Dr Reddy's Laboratories shares rise 3% after Q1; should you buy, sell or hold?

Dr Reddy’s Q1 earnings quite in line; focus now shifts to key launches ahead

Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth

Morgan Stanley initiates coverage on pharma players, bullish only on Sun Pharma

Gainers & Losers: Top 10 stocks that moved the most on June 26

Dr Reddy's shares drop 2% as Citi trims target price; sees 26% downside

Delhi High Court restrains Dr.Reddy’s, OneSource from domestic sale of weight loss drug amid patent dispute

Pharma shares sulk on Trump's plan to reduce reliance on foreign-made medicines

Dr Reddy's to introduce Sanofi's novel drug in India

Nifty Pharma settles 2% higher on exclusion from Trump's reciprocal tariffs; Lupin, IPCA Labs up 5%

GV Prasad of Dr Reddy's says 25% tariff on pharma exports could make medicines costlier for US consumers

Will Trump’s tariffs assail Indian pharma, or can it sail through?

Sell Dr Reddys; target of Rs 1150: Emkay Global Financial

Q3 Results 2025 Highlights: Adani Green Energy sees profit surge while Mankind Pharma posts revenue growth amid profit decline

Gainers & Losers: 10 stocks that moved the most on December 20

Senores IPO: A B2B play in pharma generics

Dr Reddy's unit gets penalty of Rs 28.7 lakh from Kazakhstan authority

Sell Dr Reddy's; target of Rs 1070: Emkay Global Financial

Dr Reddy's R&D expenses to stay around 8.5% in FY25, to launch key biosimilar in 2027

Dr Reddy’s enters pact with Gilead Sciences to manufacture, sell HIV drug Lenacapavir in India and 120 countries